Want to know about stem cell transplants for #Lymphoma? We recently updated our information on stem cell transplants including what they are, why they are used and the process of having one. To read our updated information 👉 https://t.co/LD4SYCwV1A

Delighted to share initial results of the CRUK ph I/II trial of aleta 001, a 1st in class CAR T engager protein at #ASH2025 ✅ Excellent safety profile ✅ No DLTs ✅ No SAEs beyond gr1 CRS ✅ Robust and sustained CAR T expansions @BioAleta @PDRennert @immunologydoc @uhbtrust

For years, the consensus was: "Ethereum is secure but slow, so it's destined to be niche 'Digital Gold'." We were wrong. We were analyzing it as a Computer (bandwidth constraints). We should have been analyzing it as a Market (economic dynamics). Here is the thesis for the

Thomas et al: non-erythrodermic Sezary syndrome (neSS) - 21 pts compared with 79 typical SS - most neSS did NOT devel >80% erythroderma (T4) FU 4.5y - ECP +/- bex commonest Rx - neSS had much higher PS compared with SS Interesting - never come across this. #ASH2025 #lymsm

Scarisbrick et al - PROCLIPI - prospec CTCL registry, 549 adv stage - 5y OS 50%, IIIA better - Prog factors: Age >60, N3, LDH incr, large cell Tx in skin - Assoc with OS, PFS - HRQoL also assoc v useful as current staging system difficult & does not prognosticate #ASH2025 #lymsm

The odd thing about this is that 75+ is deemed 'unsuitable for full dose chemo'. I give plenty of 75-79y DLBCL patients full dose R-CHOP / Pola-R-CHP!

Why settle for impressions when you can get engagement? We help crypto brands get high-quality traffic that converts. Simple.

Cheah et al: EPCORE NHL-2, Epcor+R-miniCHOP 1L DLBCL - 75y+ or 65+ with co-morb, epcor 8 cycles - Med FU 33mo, med age 81y - CRR 86%, 2y PFS 76% - 29% G2 CRS (quite high), no ICANs - 40% G3/4 infectn V encouraging data, again tox perhaps higher than in other gps. #ASH2025 #lymsm

CML, Hodgkin and now Myeloma with similar, almost rectangular KM-curves. I love it.

Vitolo - EPCORE DLBCL3, fixed duration epcor, 1L DLBCL - 80y+ or 75-80y with co-morbidities - 66 pts, med age 82y, IPI 2+ 64%, med FU 18mo - CMR 62%, 1y PFS 54% - CRS 71%, ICANs 18%, G3 infectn 18% (5% G5) Active but more tox seen in elderly cohort #ASH2025 #lymsm

Sharman et al - s/c mosun PhII MorningSun study - 1L DLBCL, 80+y or 65-80 if not chemo fit - med age 82 (upper 101y!), 49 pts, FU 12.5mo - CMR 59.2%, 12mo PFS 71% - NRM 8% - no ICANS, 10% CRS (G1/2), 16% G3 infectn Highly active in high risk group. #ASH2025 #lymsm

Salt? Slush? Holiday road trips? 🎄 Slick Mist® makes cleanup fast and satisfying. Perfect for anyone who hates winter grime.

Chapuy et al - R-Pola-Glo in unfit / frail 1L DLBCL - PhII, 80 pts, not eligible full dose R-CHOP - by sGA, 91% 'unfit / frail', med age 80y - ICANS 4%, NRM 4% - 22% G3/4 infectn - 1y PFS 85% (15mo FU) - CMR 81% cycle 12 Very impressive and looks well tolerated. #ASH2025 #lymsm

Lots of exciting data on bispecific antibodies in lymphoma at #ASH25 this year - great to discuss our recent @BritSocHaem good practice paper with @wendster @SridharChaganti in this podcast - some practical tips for delivery and patient management https://t.co/KELoDPx3NA

Are you a healthcare professional working in #Lymphoma? Our interactive cutaneous T-cell lymphoma (#CTCL) map gives you details of specialist CTCL centres in the UK. Including address, location and information about treatments available 👉

My take home here is to not be too quick to assume a biologically plausible biomarker is useful in the clinic. Here it turns out BTKi is pretty active in GCB DLBCL.

https://t.co/xztebquHTT

Di Roco et al: R-CHOP+ ibrutinib (+ Mx Ibr) PhII - 18-65y, ABC COO (Nanostring), DLBCL 1L - 75 pts Rxed, 69 finished 5x RI-CHOP - 16% Rx discontinuatn - CMR at EOI 72%, 2y PFS 77.7% Positive study but hard to interpret without control arm #ASH2025 #lymsm

Brooks et al - REALBiTE, relapse outcome after glofit & epcor (BiS) - PD assoc with primary refract, refract to last line & CD20- disease - 381 pts, 189 PD - 12 alloSCT as consolidn, 8 alive & no PD (9mo FU) - At PD, poor PFS / OS & further Rx varied #ASH2025 #lymsm

Do come to what promises to be an excellent educational meeting across the haematological malignancy spectrum: the 1st SOHO UK Annual Meeting. Click here: https://t.co/5lPWMKHVJW

Missed attending #LymphomaManagement 2025? You can still catch up on all the presentation videos and download copies of the slides. Register here 👉 https://t.co/FAk3KxgHNw… @graham74GC @tobyeyre8 @OxfordHaem #LymSM

Cottereau et al - MTV in Ro-CHOP study (PTCL) - 243 pts in analysis - Baseline TMTV powerful prog for PFS & OS - But low risk still do badly! - regardless of Tfh for OS (not PFS) May help risk stratify future trials. #ASH2025 #lymsm

Shumilov et al - ASCT in Alk+ ALCL - EMBT, 1L and beyond - 282 ASCT (81 1L), 100 alloSCT - 3y PFS 75% 1L, 57% for salvage - PR vs CR no diff - allo, med age 33! 3y PFS 62%, prior ASCT no diff - no. prior lines important #ASH2025 #lymsm